Search - tctmd.com

Displaying 201 - 220 of 1213

Sort: Relevancy | Date

News Daily News

Balancing Hypertension and Fall Risk: A Delicate Dance in Elderly Patients

L.A. McKeown

April 22, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Daily News

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

Todd Neale

April 17, 2024

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Todd Neale

April 12, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Shelley Wood

April 11, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation ACC 2024

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Presenter: Michael J. Koren

April 06, 2024

News Daily News

Antihypertensives Linked to Lower Long-term Dementia Risk

Caitlin E. Cox

April 01, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Daily News

Biologic Winrevair Wins FDA Approval for Treatment of PAH

L.A. McKeown

March 27, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Conference News

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Michael O'Riordan

March 22, 2024

News Daily News

Peer Coaching May Help With BP Control in Rural Black Populations

Todd Neale

March 22, 2024

News Daily News

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

Michael O'Riordan

March 20, 2024

News Daily News

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

Todd Neale

March 15, 2024

Advertisement

Balancing Hypertension and Fall Risk: A Delicate Dance in Elderly Patients

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Tirzepatide Eases Obstructive Sleep Apnea in Patients With Obesity

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

Need a Statin for Primary Prevention? There’s an App for That

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Comparison of an “Inclisiran First” Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial

Antihypertensives Linked to Lower Long-term Dementia Risk

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Biologic Winrevair Wins FDA Approval for Treatment of PAH

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality

Peer Coaching May Help With BP Control in Rural Black Populations

FDA Approves Aprocitentan for Inadequately Controlled Hypertension

LAAO Over Meds in AF? Demographic, Clinical Factors Are at Play

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content